Clinical Trial

Deep Learning for Histopathological Classification and Prognostication of Gynaecologic Smooth Muscle Tumours

Study acronym: STUMP
Recruiting
View on ClinicalTrials.gov →
Summary
Smooth muscle tumors of the uterus that do not fit the diagnostic criteria of benignity (such as leiomyomas) or malignancy (such as leiomyosarcomas) are called STUMP (smooth muscle tumor of uncertain malignant potential). A potential solution to this problem could be the application of predictive models using artificial intelligence (AI) to aid in the histopathological classification and prognosis of gynecological smooth muscle tumors. Deep learning using convolutional neural networks represents a specific class of machine learning, in which predictive models are trained by considering small groups of pixels in digital images and iteratively identifying salient features. In this study, we aim to develop deep learning models capable of accurately subclassifying and predicting the prognosis of gynecological smooth muscle tumors, based on histopathological features of hematoxylin and eosin (H\&E) slides. The aim is to develop a diagnostic and prognostic algorithm to help pathologists better classify and diagnose uterine smooth muscle tumors and predict their clinical course.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-02.
Trial Details
NCT Number NCT06540846
Lead Sponsor Institut Bergonié
Conditions Stump
Enrollment 392 participants
Start Date 2023-12-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-15